DE69841663D1 - Verwendung von methylnaltrexon und verwandten verbindungen - Google Patents

Verwendung von methylnaltrexon und verwandten verbindungen

Info

Publication number
DE69841663D1
DE69841663D1 DE69841663T DE69841663T DE69841663D1 DE 69841663 D1 DE69841663 D1 DE 69841663D1 DE 69841663 T DE69841663 T DE 69841663T DE 69841663 T DE69841663 T DE 69841663T DE 69841663 D1 DE69841663 D1 DE 69841663D1
Authority
DE
Germany
Prior art keywords
opioid
administration
induced
side effects
methylnaltrexone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69841663T
Other languages
English (en)
Inventor
William Drell
Joseph F Foss
Michael F Roizen
Jonathan Moss
Chun-Su Yuan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arch Development Corp
UR Labs Inc
Original Assignee
Arch Development Corp
UR Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/120,703 external-priority patent/US6274591B1/en
Application filed by Arch Development Corp, UR Labs Inc filed Critical Arch Development Corp
Application granted granted Critical
Publication of DE69841663D1 publication Critical patent/DE69841663D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE69841663T 1997-11-03 1998-11-03 Verwendung von methylnaltrexon und verwandten verbindungen Expired - Lifetime DE69841663D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/962,742 US5972954A (en) 1997-11-03 1997-11-03 Use of methylnaltrexone and related compounds
US09/120,703 US6274591B1 (en) 1997-11-03 1998-07-22 Use of methylnaltrexone and related compounds
PCT/US1998/023485 WO1999022737A1 (en) 1997-11-03 1998-11-03 Use of methylnaltrexone and related compounds

Publications (1)

Publication Number Publication Date
DE69841663D1 true DE69841663D1 (de) 2010-06-24

Family

ID=25506291

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69841663T Expired - Lifetime DE69841663D1 (de) 1997-11-03 1998-11-03 Verwendung von methylnaltrexon und verwandten verbindungen

Country Status (3)

Country Link
US (1) US5972954A (de)
AT (1) ATE467415T1 (de)
DE (1) DE69841663D1 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040024006A1 (en) * 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
US20030211157A1 (en) * 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
US6559158B1 (en) * 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US6274591B1 (en) * 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
WO1999032120A1 (en) 1997-12-22 1999-07-01 Euro-Celtique, S.A. A method of preventing abuse of opioid dosage forms
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
UA55507C2 (uk) 1997-12-22 2003-04-15 Еро-Селтік, С.А. Лікарська форма для перорального введення та спосіб запобігання зловживанню пероральною опіоїдною композицією
US6451806B2 (en) 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
US6469030B2 (en) 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
EP2517710B1 (de) 2000-02-08 2015-03-25 Euro-Celtique S.A. Missbrauchssichere orale Opioidagonisten-Formulierungen
US6569449B1 (en) 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
CN1525851A (zh) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
CA2449175A1 (en) 2001-06-05 2002-12-12 University Of Chicago Use of methylnaltrexone to treat immune suppression
WO2003002100A1 (en) * 2001-06-26 2003-01-09 Farrell John J Tamper-proof narcotic delivery system
IL159917A0 (en) 2001-07-18 2004-06-20 Euro Celtique Sa Pharmaceutical combinations of oxycodone and naloxone
JP4504013B2 (ja) 2001-08-06 2010-07-14 ユーロ−セルティーク エス．エイ． 放出可能な及び封鎖されたアンタゴニストを有するオピオイドアゴニスト製剤
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
AU2002324624A1 (en) 2001-08-06 2003-02-24 Euro-Celtique S.A. Sequestered antagonist formulations
DK2939696T3 (en) 2001-10-18 2016-05-23 Nektar Therapeutics Polymer Conjugates of Opioid Antagonists
WO2004014291A2 (en) * 2002-02-04 2004-02-19 Jonathan Moss Use of methylnaltrexone in treating gastrointestinal dysfunction in equines
US20050011468A1 (en) * 2002-02-04 2005-01-20 Jonathan Moss Use of methylnaltrexone in treating gastrointestinal dysfunction in equines
DK2425821T5 (en) 2002-04-05 2018-02-12 Mundipharma As Pharmaceutical preparation containing oxycodone and naloxone
HUE038446T2 (hu) 2002-09-20 2018-10-29 Alpharma Pharmaceuticals Llc Szekvesztráló alegység és releváns kompozíciók és módszerek
US7381721B2 (en) * 2003-03-17 2008-06-03 Adolor Corporation Substituted piperidine compounds
EP1615646B2 (de) 2003-04-08 2022-07-27 Progenics Pharmaceuticals, Inc. Pharmazeutische formulierungen mit methylnaltrexon
CA2521420A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
CA2521369A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
AU2013203378B2 (en) * 2003-04-08 2016-09-15 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
TWI347201B (en) 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
US8790689B2 (en) * 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
ME00276B (me) 2003-04-30 2011-05-10 Purdue Pharma Lp Transdermalni dozni oblik otporan na promjene koje sadrže komponentu aktivnog sredstva i komponentu suprotnog sredstva na mjestu koji je ispod sloja aktivnog sredstva
US6992090B2 (en) 2003-06-16 2006-01-31 Adolor Corporation Substituted piperidine compounds and methods of their use
US8946262B2 (en) * 2003-12-04 2015-02-03 Adolor Corporation Methods of preventing and treating gastrointestinal dysfunction
US20060182692A1 (en) * 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
DK1694363T3 (en) * 2003-12-16 2014-03-24 Nektar Therapeutics Monodisperse PEGylated Naloxole Compositions
US7087749B2 (en) * 2004-03-11 2006-08-08 Adolor Corporation Substituted piperidine compounds and methods of their use
EP1604666A1 (de) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
US20060063792A1 (en) * 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
US20060205753A1 (en) * 2005-01-20 2006-09-14 Israel Robert J Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction
EP1702558A1 (de) 2005-02-28 2006-09-20 Euro-Celtique S.A. Verfahren und Vorrichtung zur Darmtätigkeitserfassung
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
CN104248763A (zh) 2005-03-07 2014-12-31 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
US7538110B2 (en) 2005-10-27 2009-05-26 Adolor Corporation Opioid antagonists
US20070185145A1 (en) * 2006-02-03 2007-08-09 Royds Robert B Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
EP2484346B1 (de) 2006-06-19 2017-02-22 Alpharma Pharmaceuticals LLC Pharmazeutische Zusammensetzungen
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
TW200815451A (en) * 2006-08-04 2008-04-01 Wyeth Corp 6-carboxy-normorphinan derivatives, synthesis and uses thereof
JP5469593B2 (ja) 2007-03-29 2014-04-16 ワイス・エルエルシー 末梢性オピオイド受容体アンタゴニストおよびその使用
CA2682125C (en) 2007-03-29 2015-06-16 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
CA2682129A1 (en) 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Crystal forms and uses thereof
WO2009051824A2 (en) * 2007-10-18 2009-04-23 Aiko Biotechnology Combination analgesic employing opioid and neutral antagonist
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
JP5358587B2 (ja) 2008-02-06 2013-12-04 プロジェニックス・ファーマシューティカルス・インコーポレイテッド （ｒ），（ｒ）−２，２’−ビス−メチルナルトレキソンの製造及び用途
JP5647098B2 (ja) 2008-03-21 2014-12-24 ザ ユニヴァーシティー オヴ シカゴ オピオイド拮抗薬とｍＴＯＲ阻害薬を用いた治療
US20110250278A1 (en) 2008-07-01 2011-10-13 University Of Chicago Particles containing an opioid receptor antagonist and methods of use
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
AR075735A1 (es) 2009-03-10 2011-04-20 Euro Celtique Sa Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso
US20100311782A1 (en) 2009-06-08 2010-12-09 Adolor Corporation Substituted piperidinylpropanoic acid compounds and methods of their use
SG10201501821RA (en) 2010-03-11 2015-05-28 Wyeth Llc Oral formulations and lipophilic salts of methylnaltrexone
US20140066475A1 (en) 2012-09-04 2014-03-06 Euro-Celtique S.A. Method For Treating Pruritus
WO2015011189A1 (en) 2013-07-23 2015-01-29 Euro-Celtique S.A. A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
AU2020268767B8 (en) 2019-05-07 2025-08-07 Bausch Health Ireland Limited Liquid oral dosage formulations of methylnaltrexone

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4176186A (en) * 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility

Also Published As

Publication number Publication date
ATE467415T1 (de) 2010-05-15
US5972954A (en) 1999-10-26

Similar Documents

Publication Publication Date Title
DE69841663D1 (de) Verwendung von methylnaltrexon und verwandten verbindungen
CA2312234A1 (en) Use of methylnaltrexone and related compounds
HK1055078A1 (zh) 使用纳布啡和鸦片拮抗剂治疗疼痛的方法
CY1109264T1 (el) Νεες μεθοδοι για την θεραπεια και αποτροπη ειλεου
WO1999011250A3 (en) Noribogaine in the treatment of pain and drug addiction
TR200103613T2 (tr) Burun içinden tatbik edilen morfini içeren farmasötik formülasyonlar ve yöntemler.
RU2005113996A (ru) Способы лечения боли введением антагониста фактора роста нервов и опиоидного анальгетика, и содержащие их композиции
DE60234183D1 (de) Verwendung von methylnaltrexon zur behandlung von immunsuppression
JPS61260025A (ja) オピオイド誘発の耐性および依存症における禁断症候群の抑制
ATE326222T1 (de) Naloxon- und naltrexon-analoga in der behandlung bei drogenmissbrauch
TR200400653T4 (tr) Farmasötik kompozisyonlar.
WO2002013801A3 (en) Method of treating the syndrome of coronary heart disease risk factors in humans
TR199801164T2 (xx) S�bstit�e edilmi� tetrasiklik tetrahidrofuran t�revleri.
RU2007149044A (ru) Твердые лекарственные формы наркотических лекарственных средств с улучшенным всасыванием при трансбуккальном введении
WO2002070524A3 (en) N-but-3-enyl norbuprenorphine and its use as analgesic
ATE314372T1 (de) Therapeutische verbindungen
NO20060913L (no) Behandling av avhengighetsabstinens
NO894295L (no) Fremgangsmaate for behandling av interstitiell cystitt.
ATE268174T1 (de) Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen
ATE465735T1 (de) Verwendung einer kombination von morphin und mindestens einem opiatantagonisten zur behandlung von opiatabhängigkeit und zur verhinderung des nicht-oralen opiatmissbrauchs bei opiatsüchtigen
NO20042758L (no) Fremgangsmate for behandling av en pasient som krever analgesi.
PL326499A1 (en) Transcutateous therapeutic system (tts) for administration of active substances used in treating narcotic dependence or drug addiction
Hanks The clinical usefulness of agonist-antagonistic opioid analgesics in chronic pain
GR3018335T3 (en) Use of a pure narcotic antagonist, e.g. nalmefene, naltrexone, naloxone or diprenorphine, in the treatment of mast cell disease.
Rozen et al. Coadministration of an opioid agonist and antagonist for pain control

Legal Events

Date Code Title Description
8364 No opposition during term of opposition